0.00Open0.00Pre Close0 Volume0 Open Interest110.00Strike Price0.00Turnover130.09%IV-54.94%PremiumDec 20, 2024Expiry Date134.13Intrinsic Value100Multiplier28DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9918Delta0.0003Gamma1.81Leverage Ratio-0.0467Theta0.0824Rho1.80Eff Leverage0.0152Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet